More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands ...

Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.

The Food and Drug Administration allows this kind of compounding ... didn't have what's called a sterile compounding license. The obesity drugs made by compounding pharmacies are given by ...